Abstract Number: 1100 • ACR Convergence 2023
A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic Rule
Background/Purpose: Distinguishing crystalline from septic arthritis is a common challenge in patients admitted with acute joint inflammation. Arthrocentesis for synovial fluid analysis is considered the…Abstract Number: 1128 • ACR Convergence 2023
Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review
Background/Purpose: Inflammatory ocular pathology (IOP) includes internal (uveitis) and external [mainly ocular surface pathology such as epi/scleritis and peripheral ulcerative keratitis (PUK)] involvement. IOP may…Abstract Number: 1129 • ACR Convergence 2023
Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study
Background/Purpose: Autoinflammatory syndromes (AIS), a group of rare rheumatic diseases driven by the innate immune system, remain understudied due to the lack of prospective cohorts.…Abstract Number: 1132 • ACR Convergence 2023
Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases
Background/Purpose: Tyrosine Kinase 2 (TYK2) is a signaling protein within the Janus kinase (JAK) family. It plays a crucial role in transmitting signals from pro-inflammatory…Abstract Number: 1120 • ACR Convergence 2023
Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients
Background/Purpose: Despite rheumatology guidelines' emphasis on treat-to-target-serum-urate (SU) levels (<6 or <5 mg/dL, urate crystal sub-saturation points), this pathophysiology-based recommendation is not accepted in primary…Abstract Number: 1093 • ACR Convergence 2023
Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases
Background/Purpose: Even though individuals with inflammatory rheumatic diseases (IRDs) were excluded from the SARS-CoV-2 vaccine trails, studies have shown that these individuals at risk of…Abstract Number: 1136 • ACR Convergence 2023
Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations
Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still…Abstract Number: 1139 • ACR Convergence 2023
From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic
Background/Purpose: SAPHO syndrome is a rare chronic inflammatory condition that affects the skin and osteoarticular structures. Despite being first described over 30 years ago, it…Abstract Number: 1137 • ACR Convergence 2023
Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is a frequent pulmonary manifestation in idiopathic inflammatory myopathies (IIM) (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den…Abstract Number: 1138 • ACR Convergence 2023
Nailfold Capillaroscopy Findings in Patients with Idiopathic Inflammatory Myopathies and Its Association to Autoantibodies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired muscle diseases, which have distinct clinical, pathological and histological features. Autoantibodies are clinically useful…Abstract Number: 1123 • ACR Convergence 2023
Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016
Background/Purpose: Pegloticase can treat uncontrolled gout but anti-drug antibodies limit urate-lowering response and put patients at risk for infusion reactions (IRs).1, 2 The first case…Abstract Number: 1144 • ACR Convergence 2023
Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years
Background/Purpose: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of adults with plaque psoriasis. Deucravacitinib…Abstract Number: 1142 • ACR Convergence 2023
A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease
Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…Abstract Number: 1147 • ACR Convergence 2023
Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function
Background/Purpose: Inflammatory musculoskeletal diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterized by physical function impairment due to progressive inflammatory and structural changes.…Abstract Number: 1148 • ACR Convergence 2023
A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…
- « Previous Page
- 1
- …
- 315
- 316
- 317
- 318
- 319
- …
- 2425
- Next Page »